Investors & Media

Press Releases

Date Title View
Toggle Summary SAGE Therapeutics Announces Pricing of Initial Public Offering View HTML
Toggle Summary SAGE Therapeutics Appoints James M. Frates to the Company's Board of Directors View HTML
Toggle Summary SAGE Therapeutics Presents Preliminary SAGE-547 Clinical Data at Epilepsy Pipeline Conference View HTML
Toggle Summary SAGE Therapeutics Appoints Thomas D. Anderson as Chief Commercial Strategy Officer View HTML
Toggle Summary SAGE Therapeutics Receives U.S. Orphan Drug Designation for Lead Compound SAGE-547 to Treat Status Epilepticus
SAGE Therapeutics Receives U.S. Orphan Drug Designation for Lead Compound SAGE-547 to Treat Status Epilepticus
View HTML
Toggle Summary SAGE Therapeutics Appoints Howard H. Pien to the Company's Board of Directors
SAGE Therapeutics Appoints Howard H. Pien to the Company's Board of Directors
View HTML
Toggle Summary SAGE Therapeutics Initiates Phase 1/2 Trial of SAGE-547 in Status Epilepticus
SAGE Therapeutics Initiates Phase 1/2 Trial of SAGE-547 in Status Epilepticus
View HTML
Toggle Summary SAGE Therapeutics Closes $38M Oversubscribed Series C Financing
SAGE Therapeutics Closes $38M Oversubscribed Series C Financing
View HTML
Toggle Summary SAGE Therapeutics to Present at the 2014 Leerink Global Healthcare Conference
SAGE Therapeutics to Present at the 2014 Leerink Global Healthcare Conference
View HTML
Toggle Summary SAGE Therapeutics to Present at the 32nd Annual J.P. Morgan Healthcare Conference
SAGE Therapeutics to Present at the 32nd Annual J.P. Morgan Healthcare Conference
View HTML